Table 4.

Adult NHL trials

Reference	Trial acronym	Phase	Risk	Regimen	EFS		PFS		OS
					Survival	%	Survival	%	Survival	%
BL
108			Low	Modified CODOX-M/IVAC × 3 + intrathecal chemotherapy	2-y	83				81
			High	Modified CODOX-M/IVAC × 4	2-y	65				73
67				CODOX-M/IVAC ± rituximab	3-y	74*; 61†
71			Low	DA-EPOCH-R		95				100
69		II	Low	Hyper-CVAD with high-dose methotrexate, high-dose cytarabine + rituximab	3-y	80				88-89
									4-y	75‡; 76§
DLBCL
109		III		R-CHOP-14 vs R-CHOP-21			2-y	75 vs 75	2-y	83 vs 81
60		III		R-ACVBP vs R-CHOP			3-y	87 vs 73	3-y	92 vs 84
110	CALGB-50303			R-CHOP vs DA-EPOCH-R	3-y	81 vs 79			3-y	85 vs 85
PMBCL
62, 111	MInT			R-CHOP	3-y	78			3-y	89
64				DA-EPOCH-R		93				100

CODOX-M/IVAC, cyclophosphamide, vincristine, and doxorubicin-methotrexate/ifosfamide, etoposide, and cytarabine; MInT, MabThera International Trial.

^*Rituximab.

^†No rituximab.

^‡Age >60 y.

^§Age <60 y.